Research Articles
Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.
stats1
stats2
stats3
stats4
Search for:
FXR452 records.
| Article ID | PMID | Source | Title | Publish Year | |
|---|---|---|---|---|---|
| A48520 | 34965924 | Drug Metab Dispos | Effects of Overexpression of Fibroblast Growth Factor 15/19 on Hepatic Drug Metabolizing Enzymes. | 2021 | Details |
| A48566 | 33930378 | Arch Biochem Biophys | Identification and characterization of novel splice variants of human farnesoid X receptor. | 2021 | Details |
| A48637 | 32616182 | Bioorg Med Chem | N1-Substituted benzimidazole scaffold for farnesoid X receptor (FXR) agonists accompanying prominent selectivity against vitamin D receptor (VDR). | 2020 | Details |
| A48652 | 32329946 | Liver Int | A novel non-bile acid FXR agonist EDP-305 potently suppresses liver injury and fibrosis without worsening of ductular reaction. | 2020 | Details |
| A48656 | 32195457 | JHEP Rep | miR-22 inhibition reduces hepatic steatosis via FGF21 and FGFR1 induction. | 2020 | Details |
| A48732 | 30353976 | ChemMedChem | Selective Optimization of Pranlukast to Farnesoid X Receptor Modulators. | 2018 | Details |
| A48743 | 30026040 | Bioorg Med Chem | Structural optimization and in vitro profiling of N-phenylbenzamide-based farnesoid X receptor antagonists. | 2018 | Details |
| A48775 | 29159825 | Hepatology | Modulation of the intestinal bile acid/farnesoid X receptor/fibroblast growth factor 15 axis improves alcoholic liver disease in mice. | 2018 | Details |
| A48818 | 27701715 | Exp Clin Endocrinol Diabetes | Hypothyroidism Induces a Moderate Steatohepatitis Accompanied by Liver Regeneration, Mast Cells Infiltration, and Changes in the Expression of the Farnesoid X Receptor. | 2016 | Details |
| A48840 | 26824277 | Future Med Chem | SAR studies on FXR modulators led to the discovery of the first combined FXR antagonistic/TGR5 agonistic compound. | 2016 | Details |
| A49259 | 35807885 | Nutrients | Enterohepatic Takeda G-Protein Coupled Receptor 5 Agonism in Metabolic Dysfunction-Associated Fatty Liver Disease and Related Glucose Dysmetabolism. | 2022 | Details |
| A49296 | 35796150 | J Intern Med | Current treatment of non-alcoholic fatty liver disease. | 2022 | Details |
| A49433 | 35750137 | J Hepatol | Immune mechanisms linking metabolic injury to inflammation and fibrosis in fatty liver disease - novel insights into cellular communication circuits. | 2022 | Details |
| A49708 | 35662935 | Front Nutr | Amelioratory Effect of Resistant Starch on Non-alcoholic Fatty Liver Disease via the Gut-Liver Axis. | 2022 | Details |
| A49732 | 35655096 | Acta Pharmacol Sin | Caffeic acid phenethyl ester suppresses intestinal FXR signaling and ameliorates nonalcoholic fatty liver disease by inhibiting bacterial bile salt hydrolase activity. | 2022 | Details |
| A49754 | 35646540 | Acta Pharm Sin B | Bile acid coordinates microbiota homeostasis and systemic immunometabolism in cardiometabolic diseases. | 2021 | Details |
| A49755 | 35646285 | World J Gastrointest Oncol | Gut microbiome in non-alcoholic fatty liver disease associated hepatocellular carcinoma: Current knowledge and potential for therapeutics. | 2022 | Details |
| A49829 | 35625757 | Biomedicines | Comparative Transcriptome Analysis Reveals That Exendin-4 Improves Steatosis in HepG2 Cells by Modulating Signaling Pathways Related to Lipid Metabolism. | 2022 | Details |
| A49864 | 35614939 | Front Pharmacol | Obeticholic Acid Induces Hepatoxicity Via FXR in the NAFLD Mice. | 2022 | Details |
| A49865 | 35614896 | Visc Med | Diagnostic and Therapy of Nonalcoholic Fatty Liver Disease: A Narrative Review. | 2021 | Details |
| A49894 | 35605722 | Mol Cell Endocrinol | Recent advances on FXR-targeting therapeutics. | 2022 | Details |
| A49942 | 35586979 | Hepatology | Hepatocellular cystathionine γ lyase/hydrogen sulfide attenuates nonalcoholic fatty liver disease by activating farnesoid X receptor. | 2022 | Details |
| A50079 | 35535063 | J Clin Exp Hepatol | Gallstone Disease in Cirrhosis-Pathogenesis and Management. | 2021 | Details |
| A50157 | 35500802 | J Ethnopharmacol | Penthorum chinense Pursh. extract attenuates non-alcholic fatty liver disease by regulating gut microbiota and bile acid metabolism in mice. | 2022 | Details |
| A50188 | 35485140 | Bioengineered | Livogrit Prevents Methionine-Cystine Deficiency Induced Nonalcoholic Steatohepatitis by Modulation of Steatosis and Oxidative Stress in Human Hepatocyte-Derived Spheroid and in Primary Rat Hepatocytes. | 2022 | Details |
| A50217 | 35469167 | JHEP Rep | Lipid alterations in chronic liver disease and liver cancer. | 2022 | Details |
| A50275 | 35447541 | Biomed Pharmacother | Obeticholic acid inhibits hepatic fatty acid uptake independent of FXR in mouse. | 2022 | Details |
| A50299 | 35439472 | Chem Biol Interact | Obeticholic acid orchestrates the crosstalk between ileal autophagy and tight junctions in non-alcoholic steatohepatitis: Role of TLR4/TGF-β1 axis. | 2022 | Details |
| A50434 | 35394106 | Chem Biodivers | Dihydroflavonoids as Bioactive Components of Penthorum chinense, a Miao Ethnomedicine, against NAFLD through Bile Acid Metabolism Pathway. | 2022 | Details |
| A50617 | 35325295 | J Gastroenterol | Systematic review and meta-analysis: analysis of variables influencing the interpretation of clinical trial results in NAFLD. | 2022 | Details |
| A50622 | 35323681 | Metabolites | Emerging Role of Nuclear Receptors for the Treatment of NAFLD and NASH. | 2022 | Details |
| A50682 | 35304191 | Mol Cell Endocrinol | Enterohepatic and non-canonical roles of farnesoid X receptor in controlling lipid and glucose metabolism. | 2022 | Details |
| A50737 | 35283218 | Mol Cell Endocrinol | Discovery of farnesoid X receptor and its role in bile acid metabolism. | 2022 | Details |
| A50747 | 35279807 | Indian J Gastroenterol | Effect of combined farnesoid X receptor agonist and angiotensin II type 1 receptor blocker on ongoing hepatic fibrosis. | 2022 | Details |
| A50750 | 35278405 | Eur J Pharmacol | Inonotus obliquus and its bioactive compounds alleviate non-alcoholic fatty liver disease via regulating FXR/SHP/SREBP-1c axis. | 2022 | Details |
| A50754 | 35277054 | Nutrients | Beneficial Activities of Alisma orientale Extract in a Western Diet-Induced Murine Non-Alcoholic Steatohepatitis and Related Fibrosis Model via Regulation of the Hepatic Adiponectin and Farnesoid X Receptor Pathways. | 2022 | Details |
| A50778 | 35269812 | Int J Mol Sci | Nuclear Receptors Linking Metabolism, Inflammation, and Fibrosis in Nonalcoholic Fatty Liver Disease. | 2022 | Details |
| A51114 | 35686937 | Hepatology | IL-31 Levels Correlate with Pruritus in Patients with Cholestatic and Metabolic Liver Diseases and is FXR Responsive in NASH. | 2022 | Details |
| A51299 | 35810782 | Metabolism | Comprehensive molecular mechanisms and clinical therapy in nonalcoholic steatohepatitis: An overview and current perspectives. | 2022 | Details |
| A51301 | 35797110 | J Med Chem | Discovery of (E)-3-(3-((2-Cyano-4'-dimethylaminobiphenyl-4-ylmethyl)cyclohexanecarbonylamino)-5-fluorophenyl)acrylic Acid Methyl Ester, an Intestine-Specific, FXR Partial Agonist for the Treatment of Nonalcoholic Steatohepatitis. | 2022 | Details |
| A51310 | 35704802 | J Med Chem | Discovery of BMS-986339, a Pharmacologically Differentiated Farnesoid X Receptor Agonist for the Treatment of Nonalcoholic Steatohepatitis. | 2022 | Details |
| A51316 | 35675500 | Clin Transl Sci | Assessment of drug-drug interaction potential with EDP-305, a farnesoid X receptor agonist, in healthy subjects. | 2022 | Details |
| A51404 | 35779659 | J Hepatol | Digital pathology with artificial intelligence analyses provides greater insights into treatment-induced fibrosis regression in NASH. | 2022 | Details |
| A51430 | 35472625 | Mol Cell Endocrinol | Immunomodulatory functions of FXR. | 2022 | Details |
| A51443 | 35348137 | Lab Chip | Integration of a microfluidic multicellular coculture array with machine learning analysis to predict adverse cutaneous drug reactions. | 2022 | Details |
| A51583 | 34869329 | Front Cell Dev Biol | Combined Analysis of Expression Profiles in a Mouse Model and Patients Identified BHMT2 as a New Regulator of Lipid Metabolism in Metabolic-Associated Fatty Liver Disease. | 2021 | Details |
| A51774 | 34219348 | Liver Int | Anti-TNFα treatment in Crohn's disease: Impact on hepatic steatosis, gut-derived hormones and metabolic status. | 2021 | Details |
| A52302 | 28892150 | J Pathol | Hepatic inflammation caused by dysregulated bile acid synthesis is reversible by butyrate supplementation. | 2017 | Details |
| A52344 | 28378930 | Hepatology | Hepatic FXR/SHP axis modulates systemic glucose and fatty acid homeostasis in aged mice. | 2017 | Details |
| A52475 | 26579439 | Acta Pharm Sin B | Bile acid nuclear receptor FXR and digestive system diseases. | 2015 | Details |
| A52512 | 26197299 | Nat Commun | Bile diversion to the distal small intestine has comparable metabolic benefits to bariatric surgery. | 2015 | Details |
| A52850 | 20699090 | Clin Chim Acta | Triglycerides and gallstone formation. | 2010 | Details |